Phase 1/2a Study to Evaluate FL-301 in Patients With Advanced Solid Tumors

Gastric Cancer Clinical Trial

Official title:

A Phase 1/2a, First-In-Human, Open Label, Multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of FL-301 in Patients With Advanced Solid Tumors

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT05181865
• Other study ID #: FL-301-1001
• Status: Withdrawn
• Phase: Phase 1/Phase 2
• Start date: January 2022
• Est. completion date: January 18, 2022

Study information

• Verified date: January 2022
• Source: Flame Biosciences
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase 1/2a, first-in-human, open-label, multicenter study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of FL-301 in patients with advanced cancer.

Description:

This is a Phase 1/2a, first-in-human, open-label, multicenter study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of FL-301 in patients with advanced cancer. The study will consist of 2 phases, Phase 1 and Phase 2a. In Phase 1, dose escalation will proceed according to a rule-based design methodology. Phase 1 will explore dosing in which a single dose of FL-301 is administered by intravenous (IV) infusion every 2 weeks (Q2W) in 4-week cycles. Patients with measurable advanced solid tumors expressing claudin 18.2 may be enrolled, with the cutoff levels further defined in the eligibility criteria. Dose escalation methodology (modified 3+3 design) will utilize prespecified dose increments. Once the RP2D has been established, Phase 2a will commence to explore preliminary evidence of antitumor efficacy and confirm the safety of FL-301. The dosing schedule will be explored in up to 3 separate patient groups of approximately 30 patients per group. Group 1 will include patients with pancreatic cancer; Group 2 will include patients with gastric cancer (including gastroesophageal junction [GEJ]); and Group 3 will include patients with any other solid tumor (primarily non-small cell lung cancer [NSCLC], ovarian, and cholangiocarcinoma with claudin 18.2 expression). Response and progression will be evaluated in this study using computerized tomography (CT) or magnetic resonance imaging (MRI) imaging per RECIST v1.1. Long-term follow-up (survival and disease status, as applicable) will be conducted up to 18 months or until death, start of new anticancer therapy, end of study, or withdrawal of consent, whichever occurs first.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: January 18, 2022
• Est. primary completion date: January 18, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

General Inclusion Criteria

Applicable to all patients in both the Phase 1 and Phase 2a parts of the study:

• Histological or cytologically confirmed locally advanced or metastatic solid tumor
• Life expectancy >12 weeks.
• Age =18 years.
• ECOG performance status 0 or 1 at screening.
• Fully vaccinated against COVID-19 at least 3 weeks before C1D1. If under consideration for a booster, the booster administration needs to be complete within the same time constraint (ie, at least 3 weeks before C1D1).
• Adequate organ function, defined as:
• Hematology: defined as absolute neutrophil count (ANC) =1.5×109/L, platelet =90×109/L, hemoglobin =9.0 g/dL (in the absence of transfusion and use of growth factors within the last 14 days of screening labs).
• Renal function defined as calculated creatinine clearance (CCr) or radioisotope glomerular filtration rate >60 mL/min/1.73 m2 calculated by Cockcroft-Gault formula or normal serum creatinine with a maximum serum creatinine of 1.5 mg/dL.
• Hepatic Function:
• Alanine aminotransferase (ALT) =2.5 × ULN; =5 × ULN if with liver metastases.
• Total bilirubin =1.5×ULN.
• Serum Electrolytes:
• Serum potassium, calcium, magnesium, and phosphate within normal limits or not worse than CTCAE v5.0 Grade 1 and asymptomatic. If values are low on the initial screening assessment, supplements may be given, if clinically appropriate, and values repeated to confirm within CTCAE v5.0 Grade 1 limits.

Specific criteria for Phase 1:

• Positive claudin 18.2 tumor expression defined as =50% of tumor cells demonstrating moderate-to-strong membranous staining (2+/3+) by IHC assay performed on sections of tumor derived from formalin fixed paraffin block.
• Pathological diagnosis (histological) of any solid tumor cancer with positive claudin 18.2 tumor expression as defined above.

Specific criteria for Phase 2a:

• Positive claudin 18.2 tumor expression defined as =70% of tumor cells demonstrating moderate-to-strong membranous staining (2+/3+) by IHC assay performed on sections of tumor derived from formalin fixed paraffin block.
• At least 1 measurable target lesion as defined by RECIST 1.1
• Disease progression or relapse following conventional chemotherapy, patient must have documented radiological progression during or after their most recent anticancer

therapy:

• Pancreatic cancer: Patient should have received at least one but no more than two systemic therapies for their metastatic diseases
• Gastric cancer (including GEJ cancer): Patient should have received at least two but no more than three systemic therapies for their metastatic diseases;
• Other solid tumor cancers: Patients with other solid tumors who have no standard therapies available Exclusion Criteria

Patients who meet any of the following criteria will be excluded:

• History of severe infusion reaction with monoclonal antibody treatment.
• Active or latent hepatitis B or active hepatitis C (test within 8 weeks of screening), or any uncontrolled infection at screening.
• Known history of HIV.
• Serious active infection at the time of treatment, or another serious underlying medical condition that would impair the ability of the patient to receive protocol treatment.
• Presence of other active cancers, or history of treatment for invasive cancer =3 years. Patients with Stage I cancer who have received definitive local treatment and are considered unlikely to recur are eligible. All patients with previously treated in situ carcinoma (ie, noninvasive) are eligible, as are patients with history of nonmelanoma skin cancer.
• Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol.
• Active central nervous system (CNS) disease involvement, defined by cerebrospinal fluid (CSF) cytology, magnetic resonance imaging (MRI) or computerized tomography (CT); patients with asymptomatic CNS metastases are eligible if they have been clinically stable for at least 4 weeks prior to the first dose of study drug and do not require interventions such as surgery, radiation or any corticosteroid therapy for management of symptoms related to CNS disease.
• Pregnant or nursing (lactating) women (Appendix B).
• Patients who received claudin 18.2 targeting agents previously.
• Prior radiotherapy:
• Non-CNS site of radiation must be completed >2 weeks prior to FL-301 infusion
• CNS directed radiation must be completed >4 weeks prior to FL-301 infusion as long as patients are asymptomatic post radiation therapy

Related Conditions & MeSH terms

• Gastric Cancer
• Pancreas Cancer
• Pancreatic Neoplasms
• Solid Tumor
• Stomach Neoplasms

Intervention

Drug:
• 1 mg/kg IV FL-301
N = 1
• 3 mg/kg IV FL-301
N = 3-6
• 10 mg/kg IV FL-301
N = 3-6
• 20 mg/kg IV FL-301
N = 3-6
• 30 mg/kg IV FL-301
N = 3-6
• RP2D, IV FL-301
Pancreatic Cancer N = 30
• RP2D, IV FL-301
Gastric Cancer (Including GEJ) N = 30
• RP2D, IV FL-301
Other Solid Tumors N = 30

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Flame Biosciences

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Phase 1 (Exploratory): ORR (CR + PR), DOR, and DCR assessed centrally by RECIST v1.1	Assess the preliminary antitumor efficacy of FL-301	Up to 12 months
Other	Phase 1 (Exploratory): Explore the predictive potential of biomarkers measured in blood and/or tumor tissue in response to FL-301	Explore the predictive potential of biomarkers measured in blood and/or tumor tissue in response to FL-301	Up to 12 months
Primary	Phase 1: The incidence of DLTs (during DLT observation period)	Determine the MTD, and/or to select an RP2D, and investigate the safety and tolerability of FL-301 in patients with advanced solid malignancies	Up to 12 months
Primary	Phase 2a (Expansion): ORR (CR + PR) assessed centrally by RECIST v1.1	Assess the preliminary antitumor efficacy of FL-301, by central RECIST v1.1	Up to 12 months
Secondary	Phase 1: Incidence of patients with TEAEs and SAEs	Characterize the safety and tolerability of FL-301	Up to 12 months
Secondary	Phase 1: Incidence of patients who develop ADAs and neutralizing ADAs during treatment with FL-301	Characterize the immunogenicity of FL-301	Up to 12 months
Secondary	Phase 1: ORR (CR + PR), DOR, and DCR assessed locally by RECIST v1.1	Assess the preliminary antitumor efficacy of FL-301	Up to 12 months
Secondary	Phase 1: PK parameters - Cmax	Characterize the PK of FL-301	Up to 12 months
Secondary	Phase 1: PK parameters - Tmax	Characterize the PK of FL-301	Up to 12 months
Secondary	Phase 1: PK parameters - AUC (0-8)	Characterize the PK of FL-301	Up to 12 months
Secondary	Phase 1: PK parameters - AUC (0-t)	Characterize the PK of FL-301	Up to 12 months
Secondary	Phase 1: PK parameters - Half-life (t1/2)	Characterize the PK of FL-301	Up to 12 months